Zepbound

2024 - 8 - 27

Zepbound: The Price Drop That Could Help You Shed Pounds and Save Dollars!

consumer healthcare - Eli Lilly - GLP-1 medications - healthcare pricing - obesity - tirzepatide - weight loss - Zepbound

Eli Lilly’s Zepbound just got a major price cut with new single-dose vials! Here's how it could change everything for your weight loss journey—without breaking the bank!

Eli Lilly is making waves with its weight loss drug, Zepbound® (tirzepatide), by announcing the release of single-dose vials that are causing quite a stir in the pharmaceutical world. Distributed through LillyDirect®, these vials are priced significantly lower than other incretin medications—by at least 50%. Imagine snagging your weight loss remedy for less than what you’d pay for a fancy dinner!

The game changer here is that Eli Lilly is cutting out the middleman and going direct to consumers. This means folks who may have been previously deterred by the soaring costs of weight loss medications can now access Zepbound without the hassle of insurance. With the 2.5 mg dose coming in at just $399 per month and the 5 mg dose at $549, Lilly aims to make effective weight loss solutions available to everyone, turning the tables on a market long dominated by hefty price tags.

In a bid to expand its customer base, Lilly’s strategy also poses a tantalizing challenge to online telehealth companies that offer compounded versions of Zepbound. This could spark a competitive drive for even more affordable options as consumers now have the chance to purchase high-quality pharmaceuticals without the insurance bottleneck. Coupled with Lilly’s innovative savings program, patients can potentially realize significant savings while venturing on their weight loss journeys.

But wait, there’s more! If you’re curious about the science behind Zepbound, here’s a fun fact: tirzepatide is a dual GIP and GLP-1 receptor agonist, which means that it not only helps to regulate sugar levels but is also effective in promoting weight loss. And did you know that weight-loss drugs like Zepbound can sometimes lead to over a 15% reduction in body weight for some users? Keep your eyes peeled for this promising new option as you set sail on your path to a healthier lifestyle!

Post cover
Image courtesy of "Investors | Eli Lilly and Company"

Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding ... (Investors | Eli Lilly and Company)

Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines ...

Post cover
Image courtesy of "ABC News"

Eli Lilly to sell Zepbound directly to consumers without insurance ... (ABC News)

Eli Lilly is announcing a new way for people to get its popular Zepbound drug.

Post cover
Image courtesy of "NBC News"

Zepbound price cut: Eli Lilly lowers cost of weight loss drug (NBC News)

Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound.

Post cover
Image courtesy of "FiercePharma"

Lilly markets single-dose Zepbound vials at a major price cut (FiercePharma)

Eli Lilly has come up with a new way of supplying its popular weight-loss drug Zepbound that the company hopes could expand access while addressing other ...

Post cover
Image courtesy of "Managed Healthcare Executive"

Lilly Introduces Zepbound Single-Dose Vial for Cash-Paying Patients (Managed Healthcare Executive)

The monthly price of the 2.5 mg Zepbound single-dose vial is $399 and the 5 mg dose is $549, which Lilly officials said is in line with the savings program ...

Post cover
Image courtesy of "BioSpace"

Lilly Looks to Expand Zepbound Supply by Offering Single-Dose Vials (BioSpace)

Through its online pharmacy LillyDirect, Eli Lilly announced Tuesday it will allow patients to purchase single-dose vials of Zepbound—without the ...

Post cover
Image courtesy of "The New York Times"

Eli Lilly's Popular Weight Loss Drug, Zepbound, Is Getting a Price Cut (The New York Times)

Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the medication.

Post cover
Image courtesy of "CNBC"

Eli Lilly releases new form of weight loss drug Zepbound for half the ... (CNBC)

Eli Lilly is offering 2.5-milligram and 5-milligram single-dose vials of Zepbound for $399 per month and $549 per month, respectively.

Post cover
Image courtesy of "Reuters"

Lilly launches vials of weight-loss drug Zepbound for as low as $399 ... (Reuters)

Eli Lilly said on Tuesday it has begun selling vials of the lowest starter dose of its popular weight-loss drug Zepbound in the United States for $399 for a ...

Eli Lilly releases single-dose vials of Zepbound at half the price of ... (Endpoints News)

Eli Lilly will begin selling single-dose vials of its drug tirzepatide, marketed as Zepbound for weight loss, and price them at least 50% lower than …

Post cover
Image courtesy of "BenefitsPro"

Eli Lilly now selling weight loss drug Zepbound at 50% discount (BenefitsPro)

In response to high demand and to help patients whose health insurance doesn't cover the new GLP-1 weight loss drugs, the drugmaker is now offering Zepbound ...

Post cover
Image courtesy of "CNN"

Lilly launches lower-price weight loss drug without injector pen (CNN)

Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company ...

Post cover
Image courtesy of "Medical Marketing and Media"

Lilly sells less expensive Zepbound to meet demand, combat ... (Medical Marketing and Media)

Lilly said the move, which will make Zepbound vials available via its telehealth platform, is meant to address drug shortages.

Post cover
Image courtesy of "pharmaceutical-technology.com"

Eli Lilly's Zepbound to be issued in single-dose vials for self-payers (pharmaceutical-technology.com)

Eli Lilly has announced the availability of Zepbound (tirzepatide) in 2.5mg and 5mg single-dose vials for self-pay for adults with obesity.

Explore the last week